NextPlat (NXPL) EBITDA Margin Growth (3y) (2018 - 2026)
Powered by 
Analysis
NextPlat (NXPL) EBITDA Margin Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 1,129.00 |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | -925.00 |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -2,128.00 |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 293.00 |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 693.00 |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 457.00 |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -230,408.00 |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | -372.00 |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 15,005.00 |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 11,239.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11,239.00 |
| Mar 31, 2026 | 3,185.00 |
| Dec 31, 2025 | 7,266.00 |
| Sep 30, 2025 | 6,783.00 |
| Jun 30, 2025 | 3,958.00 |
| Mar 31, 2025 | 836.00 |
| Dec 31, 2024 | 15,663.00 |
| Sep 30, 2024 | 4,735.00 |
| Jun 30, 2024 | -3,605.00 |
| Mar 31, 2024 | 992.00 |
| Dec 31, 2023 | -1,386.00 |
| Sep 30, 2023 | 941.00 |
| Jun 30, 2023 | -9,795.00 |
| Mar 31, 2023 | -3,002.00 |
| Dec 31, 2022 | -8,021.00 |
| Sep 30, 2022 | -7,070.00 |
| Jun 30, 2022 | -2,713.00 |
| Mar 31, 2022 | -509.00 |
| Dec 31, 2021 | -11,547.00 |
| Sep 30, 2021 | -7,899.00 |